Expression levels of circulating miR-23 and miR-223 can be applied as predictors of response to anti-TNFα therapy [110], while circulating miR-19b is a promising novel biomarker of treatment response to Janus kinase (JAK)-inhibitor baricitinib in RA patients [109]. Here, TNF is linked to rheumatoid arthritis.